All Cosmos Bio-Tech Holding Valuation
Is 4148 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 4148 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 4148 (NT$46.45) wird über unserer Schätzung des Fair Value (NT$45.63) gehandelt.
Deutlich unter dem Marktwert: 4148 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4148?
Other financial metrics that can be useful for relative valuation.
What is 4148's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$3.34b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1x |
Enterprise Value/EBITDA | 12.5x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 4148's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 20.1x | ||
6508 Huikwang | 30.3x | n/a | NT$2.8b |
6534 CH Biotech R&D | 18.9x | n/a | NT$8.8b |
1712 Sinon | 15.5x | n/a | NT$16.4b |
1722 Taiwan Fertilizer | 15.9x | n/a | NT$62.2b |
4148 All Cosmos Bio-Tech Holding | 24x | n/a | NT$3.3b |
Price-To-Earnings gegen Gleichaltrige: 4148 ist auf der Grundlage des Price-To-Earnings Verhältnisses (24.4x) im Vergleich zum Durchschnitt der Vergleichsgruppe (19.4x) teuer.
Price to Earnings Ratio vs Industry
How does 4148's PE Ratio compare vs other companies in the TW Chemicals Industry?
Price-To-Earnings gegen Industrie: 4148 ist teuer, wenn man sein Price-To-Earnings Verhältnis (23.2x) mit dem TW Chemicals Branchendurchschnitt (23.2x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is 4148's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 24x |
Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von 4148 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.